Latest Protein kinase inhibitor Stories
SUNNYVALE, Calif., Aug. 9, 2011 /PRNewswire/ -- Pharmacyclics, Inc.
SAN DIEGO, Aug. 3, 2011 /PRNewswire/ -- Proacta Incorporated and Yakult Honsha Co., Ltd.
(Ivanhoe Newswire) "“ A new study reveals that cancer patients treated with the drugs sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared. "The damage that chemotherapy does to normal, healthy cells as it treats cancer has been well documented, but the precise effect that the new class of targeted agents has on the immune system is less well known. This study helps us answer that question," Keith...
Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared.
DALLAS, June 23, 2011 /PRNewswire/ -- - ReportsnReports announces it will carry 'Multitargeted Therapies: Promiscuous Drugs and Combination Therapies'Report in its store Browse the complete 'Multitargeted Therapies: Promiscuous Drugs and Combination Therapies [http://www.reportsnreports.com/reports/89350-multitargeted-therapies-promiscuous-drugs-and-combination-therap.html ] 'Report now! Search 75000+ Market Research Reports [http://www.reportsnreports.com ]...
RIDGEFIELD, Conn., May 25 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
ROCKVILLE, Md., May 19, 2011 /PRNewswire/ -- EntreMed, Inc.
WEST PALM BEACH, Fla., April 25, 2011 /PRNewswire/ -- The ophthalmic therapeutics company Xcovery Vision announced today that Sheridan G. Snyder, OBE, Chairman and CEO, and Dr.
SINGAPORE, Feb. 28, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced that its novel dual mTOR/PI3 Kinase inhibitor SB2343 demonstrated excellent pharmacokinetic/pharmacodynamic (PK/PD) properties leading to significant anti-tumor efficacy in rapamycin-sensitive and resistant xenograft models.
SAN DIEGO, Feb. 22, 2011 /PRNewswire/ -- Proacta Incorporated and Yakult Honsha Co., Ltd.
- A political dynamiter.